Verquvo
Chemical Name | vericiguat |
Dosage Form | Tablet (oral; 2.5mg, 5mg,10mg) |
Drug Class | Miscellaneous |
System | Cardiovascular |
Company | Merck & Co. |
Approval Year | 2021 |
Indication
- To reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure
- To reduce the need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%